


### AN ENANTIOSELECTIVE SYNTHESIS OF LORACARBEF (LY163892/KT3777)

C. C. Bodurow,\* B. D. Boyer, J. Brennan, C. A. Bunnell, J. E. Burks,  
M. A. Carr, C. W. Doecke,\* T. M. Eckrich,\* J. W. Fisher, J. P. Gardner, B. J. Graves,  
P. Hines, R. C. Hoying, B. G. Jackson, M. D. Kinnick, C. D. Kochert, J. S. Lewis,  
W. D. Luke,\* L. L. Moore, J. M. Morin, Jr.,\* R. L. Nist, D. E. Prather, D. L. Sparks,  
and W. C. Vladuchick.

Lilly Research Laboratories, Eli Lilly and Co.  
Lilly Corporate Center, Indianapolis, Indiana 46285

**Summary:** An enantioselective synthesis of the new, orally absorbable, totally synthetic  $\beta$ -lactam antibiotic, loracarbef (LY163892/KT3777) is described.


Carbacephalosporins have been shown to be extremely potent antibiotic substances displaying microbiological activity comparable to that of their cephalosporin analogs.<sup>1</sup> One of these derivatives, loracarbef<sup>2</sup> (**1**: LY163892/KT3777), the 1-carbadethia-analog of cefaclor (**2**),<sup>3</sup> has been shown to be a potentially useful clinical candidate, displaying activity against a broad spectrum of microbiological pathogens. We report herein an enantioselective synthesis of loracarbef suitable for the preparation of kilogram quantities for clinical trial evaluation.



**1** X = CH<sub>2</sub>, loracarbef

**2** X = S, cefaclor

Our synthesis takes advantage of the observations of Evans and Sjogren<sup>4</sup> on the use of chiral 4-aryl-2-oxazolidinones as directing groups in asymmetric Staudinger type [2 + 2] cycloaddition reactions.<sup>5</sup> Preparation of the requisite (S)-4-phenyl-2-oxazolidinone followed directly from their work. Carbamoylation of L-(+)-phenylglycine (**3**) performed under Schotten-Baumann conditions (ClCO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>-aq. NaOH) afforded the ethyl carbamate **4** in 95% yield. Borane reduction (BH<sub>3</sub>, THF) to alcohol **5**, followed by cyclization (NaH, THF), *in situ* alkylation on nitrogen (BrCH<sub>2</sub>CO<sub>2</sub>Et), and saponification (aq. NaOH) afforded the



oxazolidinone **6** in 51% overall yield. Following activation of **6** as its acid chloride **7** and preparation of the aldimine **8**, the key cycloaddition reaction was performed. Reaction of **7** and **8** in the presence of triethylamine ( $\text{CH}_2\text{Cl}_2$ ) afforded a 92:8 diastereomer ratio (determined *in situ*) of  $\beta$ -lactams **9** and **10**, respectively. Isolation of **9** could be effected by crystallization, however, olefin reduction ( $\text{H}_2$ -Pd/C,  $\text{CH}_2\text{Cl}_2$ ) followed by selective crystallization of the saturated derivative **11** was preferred. This process afforded a 60% overall yield of **11** in 99% purity and 100% diastereomeric excess.<sup>6</sup>

Removal of the chiral auxiliary and cleavage of the benzyl group from the  $\beta$ -lactam nitrogen was accomplished in one step by Birch reduction ( $\text{Li}/\text{NH}_3$ , *t*-BuOH, THF). *In situ* acylation with phenoxyacetyl chloride (aq.  $\text{NaHCO}_3$ - $\text{CH}_3\text{CN}$ ) afforded the desired amide **12** in 78% yield. Ozonolysis and oxidative work up ( $\text{O}_3$ ,  $\text{H}_2\text{O}_2$ ,  $\text{CH}_2\text{Cl}_2$ -MeOH) afforded a 77% yield of the acid **13**. The keto-ester **14** was prepared in 80% yield by the procedure of Masamune and Brooks (carbonyl diimidazole,  $\text{Mg}(\text{O}_2\text{CCH}_2\text{CO}_2\text{PNB})_2$ , THF).<sup>7</sup> Diazotization (*p*-dodecyl- $\text{SO}_2\text{N}_3$ , TEA,  $\text{CH}_3\text{CN}$ ) of derivative **14** afforded **15** in 85% yield. A rhodium-catalyzed intramolecular carbenoid-insertion reaction ( $\text{Rh}_2(\text{O}_2\text{CC}_7\text{H}_{15})_4$ ,  $\text{CH}_2\text{Cl}_2$ )<sup>8</sup> afforded the enol **16** in 72% yield.

In contrast to a previous report,<sup>9</sup> side-chain cleavage and vinyl chloride preparation occurred in a single step without incident with Hatfield's reagent<sup>10</sup> ( $(\text{PhO})_3\text{PCl}_2$ ,  $\text{CH}_2\text{Cl}_2$ , pyridine, *i*-BuOH, HCl, EtOAc) to afford a 72% yield of nucleus hydrochloride **17**. Liberation of the free base of **17** ( $\text{Et}_3\text{N}$ , EtOH,  $\text{H}_2\text{O}$ ), followed by acylation with the isobutyl carbonic anhydride of enamine-protected D-phenylglycine (TEA, DMBA (cat.), *i*-BuOCOCl, DMF) afforded derivative **18**. The fully-protected intermediate **18** was doubly deprotected with zinc and acid, and residual methyl acetoacetate scavenged with semicarbazide [(i) Zn, HCl; (ii) semicarbazide, HCl; (iii) TEA] to afford the DMF-solvate of **1** in 75% yield. The product was recrystallized from water to afford the desired monohydrate form of the drug substance, loracarbef (**1**).

**Acknowledgements.** We thank the physical chemistry department for providing analytical and spectral data. We also thank Professor David A. Evans, Dr. Lowell D. Hatfield, and Dr. Robin D. G. Cooper for helpful discussions.

#### References and Notes

- Guthikonda, R. N.; Cama, L. D.; Christensen, B. G. *J. Am. Chem. Soc.*, **1974**, *96*, 7585; Firestone, R. A.; Fahey, J. L.; Maciejewicz, N. S.; Patel, G. S.; Christensen, B. G. *J. Med. Chem.*, **1977**, *20*, 551.
- Hirata, T.; Matsukuma, I.; Mochida, Sato, K. *27th Interscience Conference on Antimicrobial Agents and Chemotherapy*, **1987**, Abstract no. 1187; Gray, G.; Ramotar, K.; Krulicki, W.; Louie, T. J. *Ibid.* Abstract no. 1200; Quay, J. F.; Coleman, D. L.; Finch, L. S.; Indelicato, J. M.; Pasini, C. E.; Shoufler, J. R.; Sullivan, H. R.; Turner, J. C. *Ibid.* Abstract no. 1205.

3. Kukolja, S.; Chauvette, R. R. In "Chemistry and Biology of  $\beta$ -Lactam Antibiotics"; Morin, R. B.; Gorman, M., Eds.; Academic Press: New York, **1982**; Vol. 1, p 93.
4. Evans, D. A.; Sjogren, E. B. *Tetrahedron Lett.*, **1985**, 26, 3783.
5. For a review, see Holden, K. G. in "Chemistry and Biology of  $\beta$ -Lactam Antibiotics"; Morin, R. B.; Gorman, M., Eds.; Academic Press: New York, **1982**; Vol. 2, p 101.
6. Satisfactory spectral and analytical data were obtained for all new compounds; the diastereomeric excess for compound 11 was determined by HPLC analysis (on a Pirkle L-naphthylalanine column) of the corresponding 3,5-dinitrobenzamide derivative prepared by Birch reduction of 11 followed by acylation with 3,5-dinitrobenzoyl chloride.
7. Brooks, D. W.; Lu, L.; Masamune, S. *Angew. Chem. Int. Ed., Eng.*, **1979**, 18, 72
8. Ratcliffe, R. W.; Salzman, T. N.; Christensen, B. G. *Tetrahedron Lett.*, **1980**, 21, 31.
9. It has been reported that attempted chlorination of benzyl 7 $\beta$ -phenylacetamido-3-hydroxy-1-carba-1-dethiacephem-4-carboxylate was unsuccessful under a variety of conditions; Uyeo, S.; Ona, H. *Chem. Pharm. Bull.*, **1980**, 28, 1563.
10. Hatfield, L. D.; Lunn, W. H. W.; Jackson, B. G.; Peters, L. R.; Blaszcak, L. C.; Fisher, J. W.; Gardner, J. P.; Dunigan, J. M. in "Recent Advances in the Chemistry of  $\beta$ -Lactam Antibiotics"; Gregory, G. I., Ed.; The Royal Society of Chemistry: Burlington House, London, **1980**; p 109.

(Received in USA 13 December 1988)